The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis

F Haseen, L J Murray , C R Cardwell , J M O'Sullivan , M M Cantwell

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Introduction The use of androgen deprivation therapy (ADT) in the treatment of prostate cancer is associated with changes in body composition including increased fat and decreased lean mass. Limited information exists regarding the rate and extent of these changes. This systematic review was conducted to determine the effects of ADT on body composition in prostate cancer patients. Methods Literature searches were conducted on MEDLINE, EMBASE and Web of Science for studies until January 2009. Only longitudinal studies that examined ADT and body composition in prostate cancer patients were included. Data were extracted on body weight, BMI, percentage of fat mass and lean body mass. Results Sixteen studies (14 cohorts and 2 RCTs) met the inclusion criteria. Pooled data, calculated according to a random effects model, showed that ADT increased % body fat by on average 7.7% (95% CI 4.3, 11.2, from seven studies, P < 0.0001) and decreased % lean body mass by on average −2.8% (95% CI −3.6, −2.0, from six studies, P < 0.0001) but for both there was marked heterogeneity between studies (I2 = 99% I2 = 73%, respectively). Similarly, body weight (2.1%, P < 0.0001 from nine studies) and BMI (2.2%, P < 0.0001, from eight studies) increased significantly. More extensive changes were seen with longer duration of treatment. Conclusions Substantial increases in fat and declines in lean mass were observed in prostate cancer patients treated with ADT. Lifestyle changes or suitable interventions to minimize the effect of ADT on body composition need to be investigated. Implications for cancer survivors Prostate cancer survivors should be made aware of the side effect of treatment on body composition and further work is required to determine what interventions can minimize the impact of ADT on body composition and therefore what evidence based advice they should be provided with. In general, though recommendation of a healthy diet and moderate exercise is reasonable.
Original languageEnglish
Pages (from-to)128-139
Number of pages12
JournalJournal of Cancer Survivorship
Volume4
Issue number2
Early online date21 Jan 2010
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Body Composition
Androgens
Meta-Analysis
Prostatic Neoplasms
Therapeutics
Fats
Body Weight
MEDLINE
Longitudinal Studies
Survivors
Adipose Tissue
Life Style
Neoplasms
Cohort Studies
Exercise

Cite this

The effect of androgen deprivation therapy on body composition in men with prostate cancer : systematic review and meta-analysis. / Haseen, F; Murray , L J; Cardwell , C R; O'Sullivan , J M; Cantwell , M M.

In: Journal of Cancer Survivorship, Vol. 4, No. 2, 06.2010, p. 128-139.

Research output: Contribution to journalArticle

Haseen, F ; Murray , L J ; Cardwell , C R ; O'Sullivan , J M ; Cantwell , M M. / The effect of androgen deprivation therapy on body composition in men with prostate cancer : systematic review and meta-analysis. In: Journal of Cancer Survivorship. 2010 ; Vol. 4, No. 2. pp. 128-139.
@article{759130674ad448c9b392e753b23f3ebf,
title = "The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis",
abstract = "Introduction The use of androgen deprivation therapy (ADT) in the treatment of prostate cancer is associated with changes in body composition including increased fat and decreased lean mass. Limited information exists regarding the rate and extent of these changes. This systematic review was conducted to determine the effects of ADT on body composition in prostate cancer patients. Methods Literature searches were conducted on MEDLINE, EMBASE and Web of Science for studies until January 2009. Only longitudinal studies that examined ADT and body composition in prostate cancer patients were included. Data were extracted on body weight, BMI, percentage of fat mass and lean body mass. Results Sixteen studies (14 cohorts and 2 RCTs) met the inclusion criteria. Pooled data, calculated according to a random effects model, showed that ADT increased {\%} body fat by on average 7.7{\%} (95{\%} CI 4.3, 11.2, from seven studies, P < 0.0001) and decreased {\%} lean body mass by on average −2.8{\%} (95{\%} CI −3.6, −2.0, from six studies, P < 0.0001) but for both there was marked heterogeneity between studies (I2 = 99{\%} I2 = 73{\%}, respectively). Similarly, body weight (2.1{\%}, P < 0.0001 from nine studies) and BMI (2.2{\%}, P < 0.0001, from eight studies) increased significantly. More extensive changes were seen with longer duration of treatment. Conclusions Substantial increases in fat and declines in lean mass were observed in prostate cancer patients treated with ADT. Lifestyle changes or suitable interventions to minimize the effect of ADT on body composition need to be investigated. Implications for cancer survivors Prostate cancer survivors should be made aware of the side effect of treatment on body composition and further work is required to determine what interventions can minimize the impact of ADT on body composition and therefore what evidence based advice they should be provided with. In general, though recommendation of a healthy diet and moderate exercise is reasonable.",
author = "F Haseen and Murray, {L J} and Cardwell, {C R} and O'Sullivan, {J M} and Cantwell, {M M}",
year = "2010",
month = "6",
doi = "10.1007/s11764-009-0114-1",
language = "English",
volume = "4",
pages = "128--139",
journal = "Journal of Cancer Survivorship",
issn = "1932-2259",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - The effect of androgen deprivation therapy on body composition in men with prostate cancer

T2 - systematic review and meta-analysis

AU - Haseen, F

AU - Murray , L J

AU - Cardwell , C R

AU - O'Sullivan , J M

AU - Cantwell , M M

PY - 2010/6

Y1 - 2010/6

N2 - Introduction The use of androgen deprivation therapy (ADT) in the treatment of prostate cancer is associated with changes in body composition including increased fat and decreased lean mass. Limited information exists regarding the rate and extent of these changes. This systematic review was conducted to determine the effects of ADT on body composition in prostate cancer patients. Methods Literature searches were conducted on MEDLINE, EMBASE and Web of Science for studies until January 2009. Only longitudinal studies that examined ADT and body composition in prostate cancer patients were included. Data were extracted on body weight, BMI, percentage of fat mass and lean body mass. Results Sixteen studies (14 cohorts and 2 RCTs) met the inclusion criteria. Pooled data, calculated according to a random effects model, showed that ADT increased % body fat by on average 7.7% (95% CI 4.3, 11.2, from seven studies, P < 0.0001) and decreased % lean body mass by on average −2.8% (95% CI −3.6, −2.0, from six studies, P < 0.0001) but for both there was marked heterogeneity between studies (I2 = 99% I2 = 73%, respectively). Similarly, body weight (2.1%, P < 0.0001 from nine studies) and BMI (2.2%, P < 0.0001, from eight studies) increased significantly. More extensive changes were seen with longer duration of treatment. Conclusions Substantial increases in fat and declines in lean mass were observed in prostate cancer patients treated with ADT. Lifestyle changes or suitable interventions to minimize the effect of ADT on body composition need to be investigated. Implications for cancer survivors Prostate cancer survivors should be made aware of the side effect of treatment on body composition and further work is required to determine what interventions can minimize the impact of ADT on body composition and therefore what evidence based advice they should be provided with. In general, though recommendation of a healthy diet and moderate exercise is reasonable.

AB - Introduction The use of androgen deprivation therapy (ADT) in the treatment of prostate cancer is associated with changes in body composition including increased fat and decreased lean mass. Limited information exists regarding the rate and extent of these changes. This systematic review was conducted to determine the effects of ADT on body composition in prostate cancer patients. Methods Literature searches were conducted on MEDLINE, EMBASE and Web of Science for studies until January 2009. Only longitudinal studies that examined ADT and body composition in prostate cancer patients were included. Data were extracted on body weight, BMI, percentage of fat mass and lean body mass. Results Sixteen studies (14 cohorts and 2 RCTs) met the inclusion criteria. Pooled data, calculated according to a random effects model, showed that ADT increased % body fat by on average 7.7% (95% CI 4.3, 11.2, from seven studies, P < 0.0001) and decreased % lean body mass by on average −2.8% (95% CI −3.6, −2.0, from six studies, P < 0.0001) but for both there was marked heterogeneity between studies (I2 = 99% I2 = 73%, respectively). Similarly, body weight (2.1%, P < 0.0001 from nine studies) and BMI (2.2%, P < 0.0001, from eight studies) increased significantly. More extensive changes were seen with longer duration of treatment. Conclusions Substantial increases in fat and declines in lean mass were observed in prostate cancer patients treated with ADT. Lifestyle changes or suitable interventions to minimize the effect of ADT on body composition need to be investigated. Implications for cancer survivors Prostate cancer survivors should be made aware of the side effect of treatment on body composition and further work is required to determine what interventions can minimize the impact of ADT on body composition and therefore what evidence based advice they should be provided with. In general, though recommendation of a healthy diet and moderate exercise is reasonable.

U2 - 10.1007/s11764-009-0114-1

DO - 10.1007/s11764-009-0114-1

M3 - Article

VL - 4

SP - 128

EP - 139

JO - Journal of Cancer Survivorship

JF - Journal of Cancer Survivorship

SN - 1932-2259

IS - 2

ER -